{"name":"Ascentage Pharma Group Inc.","slug":"ascentage-pharma-group-inc","ticker":"","exchange":"","domain":"ascentagepharma.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"APG-115","genericName":"APG-115","slug":"apg-115","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"},{"name":"APG-1252","genericName":"APG-1252","slug":"apg-1252","indication":"Solid tumors","status":"phase_1"},{"name":"APG-2575(Lisaftoclax )","genericName":"APG-2575(Lisaftoclax )","slug":"apg-2575-lisaftoclax","indication":"Relapsed or refractory acute myeloid leukemia (AML)","status":"phase_3"},{"name":"Azacitidine Injection","genericName":"Azacitidine Injection","slug":"azacitidine-injection","indication":"Myelodysplastic syndromes (MDS)","status":"marketed"},{"name":"Lisaftoclax (APG-2575)","genericName":"Lisaftoclax (APG-2575)","slug":"lisaftoclax-apg-2575","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"lisaftoclax +BTK inhibitor","genericName":"lisaftoclax +BTK inhibitor","slug":"lisaftoclax-btk-inhibitor","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"APG 2575 ramp up arm","genericName":"APG 2575 ramp up arm","slug":"apg-2575-ramp-up-arm","indication":"Other","status":"phase_1"},{"name":"APG2575","genericName":"APG2575","slug":"apg2575","indication":"Other","status":"phase_2"},{"name":"APG-3288","genericName":"APG-3288","slug":"apg-3288","indication":"Other","status":"phase_1"},{"name":"APG-5918","genericName":"APG-5918","slug":"apg-5918","indication":"Other","status":"phase_1"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Rd","genericName":"Rd","slug":"rd","indication":"Hematologic malignancies (specific indications pending confirmation)","status":"marketed"}]}],"pipeline":[{"name":"APG 2575 ramp up arm","genericName":"APG 2575 ramp up arm","slug":"apg-2575-ramp-up-arm","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APG-115","genericName":"APG-115","slug":"apg-115","phase":"phase_2","mechanism":"APG-115 is a small molecule inhibitor of BCL-2 family proteins.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"APG2575","genericName":"APG2575","slug":"apg2575","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APG-1252","genericName":"APG-1252","slug":"apg-1252","phase":"phase_1","mechanism":"APG-1252 is a Bcl-2 and Bcl-xL inhibitor that induces apoptosis in cancer cells.","indications":["Solid tumors"],"catalyst":""},{"name":"APG-2575(Lisaftoclax )","genericName":"APG-2575(Lisaftoclax )","slug":"apg-2575-lisaftoclax","phase":"phase_3","mechanism":"APG-2575 (Lisaftoclax) is a BCL-2 family protein inhibitor that promotes apoptosis by blocking anti-apoptotic proteins in cancer cells.","indications":["Relapsed or refractory acute myeloid leukemia (AML)","Relapsed or refractory B-cell lymphomas"],"catalyst":""},{"name":"APG-3288","genericName":"APG-3288","slug":"apg-3288","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APG-5918","genericName":"APG-5918","slug":"apg-5918","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Azacitidine Injection","genericName":"Azacitidine Injection","slug":"azacitidine-injection","phase":"marketed","mechanism":"Azacitidine is a DNA methyltransferase inhibitor that causes hypomethylation of DNA and promotes differentiation and apoptosis of abnormal hematopoietic cells.","indications":["Myelodysplastic syndromes (MDS)","Chronic myelomonocytic leukemia (CMML)","Acute myeloid leukemia (AML)"],"catalyst":""},{"name":"Lisaftoclax (APG-2575)","genericName":"Lisaftoclax (APG-2575)","slug":"lisaftoclax-apg-2575","phase":"phase_3","mechanism":"Lisaftoclax is a BCL-2 family protein inhibitor that promotes apoptosis by blocking anti-apoptotic proteins in cancer cells.","indications":["Chronic lymphocytic leukemia (CLL)","Small lymphocytic lymphoma (SLL)","Acute myeloid leukemia (AML)"],"catalyst":""},{"name":"Rd","genericName":"Rd","slug":"rd","phase":"marketed","mechanism":"Rd is a BCL-2 family protein inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins.","indications":["Hematologic malignancies (specific indications pending confirmation)"],"catalyst":""},{"name":"lisaftoclax +BTK inhibitor","genericName":"lisaftoclax +BTK inhibitor","slug":"lisaftoclax-btk-inhibitor","phase":"phase_3","mechanism":"Lisaftoclax is a BCL-2 inhibitor combined with a BTK inhibitor to promote apoptosis in cancer cells while blocking B-cell survival signaling.","indications":["Chronic lymphocytic leukemia (CLL)","Small lymphocytic lymphoma (SLL)","Other B-cell malignancies"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-08","type":"pipeline","source":"simplywall.st","summary":"Assessing Ascentage Pharma Group International’s Valuation After Recent Share Price Momentum - simplywall.st","headline":"Assessing Ascentage Pharma Group International’s Valuation After Recent Share Price Momentum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQeU4yOWNfMzI1ZGtYT0Y0STdaWDRiUU1CYWNxZ2lVQnRucjdhZ2lqd2g0SE1VX2R4VEd0REZLV0JfRVpUblE3cDRlakFNR0lfSXJvQWxiRXdaM2xpemtWQVpqa2IyUWFNT1BrRWpQcF9QYkU0T0k3NTNwQUxXdWlaNnEyRHE4Qk9WWFRROWEzYzlKTnpTcV9WWmRHT1BZcVR0bGJDUzJ3ckN5RW44Ql8wVjE3YmdmOUJLaTdZbU9uRXlfVjBmNkZoUFpn?oc=5","date":"2026-04-06","type":"deal","source":"MarketBeat","summary":"Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Should You Buy? - MarketBeat","headline":"Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Should You Buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPNjV6MmVWd1lzWElqUWZGUFRlTjNuelBUTHRMUnAtc1ZXY2dCT3NlZXVPQlRoRk9XLWZNNVV0cmE4SGQ4RTE2S2Zjb2JnZDF4U0dydk9QZW1IaVJjeHJiTjFNRXAxUG91aE9wSnBsOGlvRkhlZFlJbEp4czhJTEZxSHQ0TGktcEdQN25QRE5TRDgzVTFCbUdRaDdHdllINmt2a2RXQVRkbjNHRldqT01DallKZENaOEZxWlFZRlNrOWRsTkIxRFZMUk9hZw?oc=5","date":"2026-04-01","type":"pipeline","source":"Stock Titan","summary":"Ascentage Pharma (AAPG) shifts principal Hong Kong business address - Stock Titan","headline":"Ascentage Pharma (AAPG) shifts principal Hong Kong business address","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOUzNVRk5TNDJOVDZvLURLcWVfdE9wUW9zMHhoTkhFSkRuOWtmeE9VY2d3azNtTVd3TGF0VV9RbUtOMnRaZmZub2txakxqLVlCQnZnNUlSSVlwX2dlTHd0cEE1ZlVXMmhNYjQxZHgtNTNBc1Y4QktyYzFuS1pqSmFUTGs0aW1nU0NoQzlqNFAtbEUwRlNwbTNnYjVWMkEzVC1HekRMbGNIM2xkRUNyRHZEQWtYYzNYV2hTdWUzRDZhMUp3YlRoZ0lyZFFiNzRWSWdmdHNCSkxsRHFxRDZKZkFBWDBR?oc=5","date":"2026-04-01","type":"pipeline","source":"TipRanks","summary":"Ascentage Pharma Relocates Hong Kong Principal Office and Highlights Global Governance Standards - TipRanks","headline":"Ascentage Pharma Relocates Hong Kong Principal Office and Highlights Global Governance Standards","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNcDgwU3NRX1ZINnpZSjNuRVlVYThINVFocHV2dWc3NUdvNk1IeUY3QXNCS2pZWlZiRGRxUTlSclNaR3JfYlFZODNaQnNfREVyZlRwWi1wbzU0WGl3TkcyLV9vVkljbHVxdWdQcFVJeTQ5T0FoSzZkT18wQTZmWFJZYWI4V2dLS1NuRTFsRVF4dXE1VWkyRlEtdHpSMHQzdXZZTHNFTGZGTlVQLUlPSkhYRDRRaHl0QTdINldHVU1RbWtHc19IRHQxWmFOZWNTeXpI?oc=5","date":"2026-03-30","type":"pipeline","source":"MarketBeat","summary":"Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Here's What Happened - MarketBeat","headline":"Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Here's What Happened","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPN2FBbzFZdGxLV2lONm0wUXFDM2ZkcHRadTZab3FHM3ZhNmNsZFNVV2lmMWQ2MVhnaFNJZ3ZnVzdOOGZkTGRSZXlHZnNGbHpmM3NWWEJaX19lSDg5MTdWR25tWVVGaml3YlR4LXRKYk81UmZObk5ZWVdFQlc3d0NEOUhIRXJCX0VkXzd1YkFkenJfa0hXWS1GZ2RvVGRTU0RJRkM4QkVlUTZPT0xzUVp4bzY4Q3ZfYk5NRU9ILTdLT2RxZXZXcE1XbTlWSE5WS3JvUXJPNFh0U09iZWFtaE9tdXFCNVBwNHJxNHJiX2Q0STh5Si1iVk1Oc2Fn?oc=5","date":"2026-03-28","type":"regulatory","source":"The Globe and Mail","summary":"BTIG Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail","headline":"BTIG Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxQbldvUXJacU0tNnhOM0tMZFpxeFdpTUhhcWFPbzYwWVNOaVdOR0swcVV4MDNpdjlpNHZzUllWNHdvT1FobUNxeXVvb3lFVzNGUXVJTmg5WEljNkdJaVF2ZE5zemRfenhwN3NGZHgwbV9mb0cwenM3X05YVmsxMy1XN29LNU1iWjhLcXJUNjBkdzRLVXJfYVRiRkN1ckxRY1VDUHRyaTVOUnFwRVF1WnVuUUswOUZnYmwzR1RhYnVhb1M4TE9XV0I2Tk5nRnRVX1dhaW1PeW03Z2RlMUNucUJlZzNMd0xJVzY4S1FnVnh2WDBjbVJwWlpLSUZSTXV0azRZeFhwdE5OdUg3dw?oc=5","date":"2026-03-28","type":"regulatory","source":"The Globe and Mail","summary":"Truist Financial Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail","headline":"Truist Financial Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPQjVqVC1KS1dDdkFWbEpEOVI4akpOeG9OTGFlNURNVDdrS2Y1eXdxVEhpSTg0dWJuNWUyR2plYXlyNk9OYlV6QmVWa3VUX2FtYndURXhVUlB3MmlhdUZYeGMxcGRBR1N5aDFTZEswMWdfdXhteU9QSjZibDhHS2hNaUZDZDlrRDBOUmREa29Db1pfYTN5LVJaNHpNMGJIOU9zam05MTdBb0NBcHdRSFJrWDhKWWw5a1RHck13dFhzOEJDcEpFLVA5a3lIWQ?oc=5","date":"2026-03-26","type":"pipeline","source":"Stock Titan","summary":"Ascentage Pharma (NASDAQ: AAPG) deepens 2025 loss amid heavy R&D spend - Stock Titan","headline":"Ascentage Pharma (NASDAQ: AAPG) deepens 2025 loss amid heavy R&D spend","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxPbXNObjJWbHpJak5oOGRDRmhUN2tIQWZhWlhNeDlWMWdUdWRRbzNSUG5MdVFTaXRGU2tJZTB4V2d3V1FGMUxtcFBCYlVzM1RxUm1Ndkl2azBlYlJvci1xTndQS0lXSTBCSlpKemdBdU11N0d4MU9yN0xHTTdWZHBOVHl6TFVFMlpOcUhhdTlaVGpBUW4wX1phSU1ueGIzazVIQTQwVkVrTTdFNXNhT0VsenRPS0xBSEFzMHZMRnlULUVGZnNPWTFLTFo1RlAtdFJzSy1ISFlqNW9HT0dEY0FHcUJWa0NUeGd6Tmk0dHNIRjdwc1p6WTRmWVFhSUF6dw?oc=5","date":"2026-03-25","type":"pipeline","source":"GlobeNewswire","summary":"Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates - GlobeNewswire","headline":"Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxNaUVBdWQ2bjN1OFVXVlBCeE1NTTZiMXFvVk5XcVVrVTluZWRBQTJTSkMzbXB5MnN6dE1pWHFfcERtb1lwOG9CMDg0RXdMd3NKRmV3OFE2SFQ1LTRDX2JIZ1VjeUJsWW9Id2lMbnJkRzVjVldnc0s2NGR6OXVlZUVrZGJuSDNhTlFmeGpCQ0RZeGpEamdEcThHQjQxdExUbXUwdnVDV3N2VHZGd0lvWjVwZjh0WnczZlBOZlczNDBvY3YxVzdQNkM2dWRUbDdSRi01dXBiMVd1TTBMYW14Q1Z3YUFOY1NfVzhhbWtNTUs5c0hVS19qMml4N1hGMVdyYmtqOHozZFh1MjdQd2lGUzJoOFk0dmdOUQ?oc=5","date":"2026-03-11","type":"pipeline","source":"GlobeNewswire","summary":"Ascentage Pharma to Report Full Year 2025 Unaudited - GlobeNewswire","headline":"Ascentage Pharma to Report Full Year 2025 Unaudited","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPOE1aOG9nejA4aUNJWmtBdmJWbk1ZSy1EWXBfS0NfN1BZM3ZGendsTV8tem8wZTM3YUkxSDI2d0FxUm1KSTdCX21VNXJSUFZ5WE9JdmRaTnMycGhvUUNkYWxKcjJBZ0lKYVRKLVhBR1VJRkNjRHJtYmVnVFQwbHZwVlBGVl9LdUliVUhlZGJ4SHpBZm8?oc=5","date":"2026-02-23","type":"pipeline","source":"Yahoo Finance","summary":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences - Yahoo Finance","headline":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOTS05dlBZS0plNEJYbnZVQWtVMm83eURBRVBqVnZ2Y0hQN2YxTFVnM0xTZEFBVFg3SUloUzBJcFN4V0txOFBLNXNIbFFUcEp1OEt0SXpQMTQzaVF4S0pRbVZjaFpyTlBrOXFaUXVOQl9sMUdSR3dvRWhOVEZTc3FOS3BnQVE?oc=5","date":"2026-01-15","type":"pipeline","source":"Yahoo Finance","summary":"Is Ascentage Pharma Group (SEHK:6855) Price Swings Creating A Valuation Opportunity Now - Yahoo Finance","headline":"Is Ascentage Pharma Group (SEHK:6855) Price Swings Creating A Valuation Opportunity Now","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_1":4,"phase_2":2,"phase_3":3,"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}